133 related articles for article (PubMed ID: 31472018)
1. A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics.
Wu X; Park M; Sarbassova DA; Ying H; Lee MG; Bhattacharya R; Ellis L; Peterson CB; Hung MC; Lin HK; Bersimbaev RI; Song MS; Sarbassov DD
Int J Cancer; 2020 May; 146(10):2822-2828. PubMed ID: 31472018
[TBL] [Abstract][Full Text] [Related]
2. Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.
Burska AN; Ilyassova B; Dildabek A; Khamijan M; Begimbetova D; Molnár F; Sarbassov DD
Cells; 2022 Nov; 11(21):. PubMed ID: 36359850
[TBL] [Abstract][Full Text] [Related]
3. The Vitamin C Enantiomers Possess a Comparable Potency in the Induction of Oxidative Stress in Cancer Cells but Differ in Their Toxicity.
Begimbetova D; Burska AN; Baltabekova A; Kussainova A; Kukanova A; Fazyl F; Ibragimova M; Manekenova K; Makishev A; Bersimbaev RI; Sarbassov DD
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473779
[TBL] [Abstract][Full Text] [Related]
4. The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth.
Begimbetova D; Kukanova A; Fazyl F; Manekenova K; Omarov T; Burska AN; Khamijan M; Gulyayev A; Yermekbayeva B; Makishev A; Saliev T; Batyrbekov K; Aitbayev C; Spatayev Z; Sarbassov D
Biomed Res Int; 2022; 2022():9426623. PubMed ID: 36619305
[TBL] [Abstract][Full Text] [Related]
5. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.
Aguilera O; Muñoz-Sagastibelza M; Torrejón B; Borrero-Palacios A; Del Puerto-Nevado L; Martínez-Useros J; Rodriguez-Remirez M; Zazo S; García E; Fraga M; Rojo F; García-Foncillas J
Oncotarget; 2016 Jul; 7(30):47954-47965. PubMed ID: 27323830
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
[TBL] [Abstract][Full Text] [Related]
7. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
8. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
[TBL] [Abstract][Full Text] [Related]
9. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
11. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
12. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
Yun J; Mullarky E; Lu C; Bosch KN; Kavalier A; Rivera K; Roper J; Chio II; Giannopoulou EG; Rago C; Muley A; Asara JM; Paik J; Elemento O; Chen Z; Pappin DJ; Dow LE; Papadopoulos N; Gross SS; Cantley LC
Science; 2015 Dec; 350(6266):1391-6. PubMed ID: 26541605
[TBL] [Abstract][Full Text] [Related]
13. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
Jung SA; Lee DH; Moon JH; Hong SW; Shin JS; Hwang IY; Shin YJ; Kim JH; Gong EY; Kim SM; Lee EY; Lee S; Kim JE; Kim KP; Hong YS; Lee JS; Jin DH; Kim T; Lee WJ
Free Radic Biol Med; 2016 Jun; 95():200-8. PubMed ID: 27012422
[TBL] [Abstract][Full Text] [Related]
14. Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer.
Xu C; Wang X; Zhou Y; Chen FX; Wang H; Li K; Fan H; Tang X; Jiang G; Zhang J
Oncogene; 2019 Nov; 38(47):7249-7265. PubMed ID: 31420604
[TBL] [Abstract][Full Text] [Related]
15. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
Ambrogio C; Gómez-López G; Falcone M; Vidal A; Nadal E; Crosetto N; Blasco RB; Fernández-Marcos PJ; Sánchez-Céspedes M; Ren X; Wang Z; Ding K; Hidalgo M; Serrano M; Villanueva A; Santamaría D; Barbacid M
Nat Med; 2016 Mar; 22(3):270-7. PubMed ID: 26855149
[TBL] [Abstract][Full Text] [Related]
17. The X
Zheng Z; Luo G; Shi X; Long Y; Shen W; Li Z; Zhang X
Cell Oncol (Dordr); 2020 Feb; 43(1):95-106. PubMed ID: 31617161
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
